Shattuck Labs (NASDAQ:STTK) Coverage Initiated at Leerink Partners

Leerink Partners assumed coverage on shares of Shattuck Labs (NASDAQ:STTK) in a research note released on Monday, MarketBeat reports. The brokerage issued an outperform rating and a $4.00 price target on the stock.

Shattuck Labs Price Performance

NASDAQ STTK opened at $1.17 on Monday. The stock’s 50-day moving average is $1.25 and its 200-day moving average is $1.61. Shattuck Labs has a one year low of $0.94 and a one year high of $11.76. The firm has a market cap of $55.86 million, a P/E ratio of -0.76 and a beta of 1.66.

Institutional Investors Weigh In On Shattuck Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of STTK. GSA Capital Partners LLP acquired a new stake in Shattuck Labs in the 3rd quarter valued at approximately $121,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Shattuck Labs by 44.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock valued at $622,000 after buying an additional 54,505 shares during the last quarter. FMR LLC raised its position in Shattuck Labs by 0.4% in the 3rd quarter. FMR LLC now owns 7,159,090 shares of the company’s stock valued at $24,985,000 after buying an additional 26,460 shares during the last quarter. MetLife Investment Management LLC raised its position in Shattuck Labs by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock valued at $86,000 after buying an additional 13,859 shares during the last quarter. Finally, Atom Investors LP acquired a new stake in Shattuck Labs in the 3rd quarter valued at approximately $35,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.